October 22 2013 Issue

1) Dementia management quality measures and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Amy Sanders about her paper on dementia management quality measures. Dr. Adam Numis is reading our e-Pearl of the week about Leber's hereditary optic neuropathy. In the next part of the podcast Dr. Mark Keegan interviews Dr. Alasdair Coles about alemtuzumab treatment of multiple sclerosis. The participants had nothing to disclose except Drs. Burns, Sanders, Numis, Keegan, and Coles.Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Dr. Sanders is a member of a federal advisory committee (MEDCAC); received honoraria for serving on peer-review panels from the CMMI and PCORI; and research support from the Einstein CTSA Grant from the National Center for Research Resources, a component of the NIH and NIH roadmap for Medical Research; loan repayment support from LRP/NIA. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Coles is a co-editor of Advances in Clinical Neuroscience and Rehabilitation; serves on the scientific advisory board for the Multiple Sclerosis Society of GB & NI, International Society for Neuroimmunology, Genzyme Corporation steering committee, UK Advisory Board, Merck Serono; is a consultant and receives speakers' honoraria from Nil, Merck Serono, Genzyme Corporation, Bayer Schering Pharma; and has a patent for IL-21 as a marker of autoimmunity after alemtuzumab treatment.